Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

Upregulation of inhibitory receptors, such as lymphocyte activation gene-3 (LAG-3), may limit the antitumor activity of therapeutic antibodies targeting the programmed cell death protein-1 (PD-1) pathway. We describe the binding properties of ezabenlimab, an anti-human PD-1 antibody, and BI 754111,...

Full description

Saved in:
Bibliographic Details
Main Authors: Markus Zettl, Melanie Wurm, Otmar Schaaf, Sven Mostböck, Iñigo Tirapu, Ilse Apfler, Ivo C. Lorenz, Lee Frego, Cynthia Kenny, Michael Thibodeau, Elisa Oquendo Cifuentes, Markus Reschke, Jürgen Moll, Norbert Kraut, Anne Vogt, Jonathon D. Sedgwick, Irene C. Waizenegger
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
PD-1
LAG-3
ezabenlimab
BI 754091
BI 754111
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2080328
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items